Sulopenem

Drug Profile

Sulopenem

Alternative Names: CP-70,429; PF-03709270; PF-3,709,270

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Iterum Therapeutics; Pfizer
  • Class Antibacterials; Penems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gram-negative infections; Gram-positive infections
  • Discontinued Bacterial infections

Most Recent Events

  • 05 Jan 2017 Preclinical trials in Gram-negative infections in Ireland (IV) before January 2017
  • 05 Jan 2017 Preclinical trials in Gram-negative infections in Ireland (PO) before January 2017
  • 05 Jan 2017 Preclinical trials in Gram-positive infections in Ireland (IV) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top